Table 2.
Number of biopsied IPF-patients in the clinical trials conducted during the past decade
| Study | Number of patients | Number (n)/% of biopsied patients |
|---|---|---|
|
Pirfenidone |
107 |
- pirfenidone: n = 15/21% |
| Azuma et al., AJRCCM 2005 |
- placebo: n = 8/23% |
|
|
Pirfenidone |
267 |
- high dose: n = 26/24% |
| Taniguchi et al., Eur Respir J 2010 |
- low dose: n = 16/29% |
|
| - placebo: n = 28/27% | ||
|
Pirfenidone |
CAPACITY I |
CAPACITY I |
| Noble et al., Lancet 2011 |
435 |
- 1197 mg: n = 32/37% |
| CAPACITY I |
CAPACITY II |
- 2403 mg: n = 86/49% |
| CAPACITY II |
334 |
- placebo: n = 85/49% CAPACITY II |
| - pirfenidone: n = 94/55% | ||
| - placebo: n = 94/54% | ||
|
Triple-therapy |
155 |
- triple therapy: n = 38/48% |
| Demedts et al., NEJM 2005 |
- control: n = 35/47% |
|
| IFIGENIA |
- excluded patients: n =24/89% |
|
|
Interferon gamma-1b |
330 |
- IFN-γ-1b: 62% |
| Raghu et al., NEJM 2004 |
- placebo: 67% |
|
|
Interferon gamma-1b |
826 |
- IFN-γ-1b: n = 305/55% |
| King et al., |
- placebo n = 151/55% |
|
| Lancet 2009 | ||
| INSPIRE | ||
|
Bosentan |
158 |
- bosentan: 68% |
| King et al., |
- placebo: 60% |
|
| AJRCCM 2008 | ||
| BUILD-1 | ||
|
Imatinib |
119 |
- imatinib: n = 25/42% |
| Daniels et al., |
- placebo: n = 29/48% |
|
| AJRCCM 2010 | ||
|
Etanercept |
88 |
- etanercept: n = 28/46% |
| Raghu et al., |
- placebo: n = 23/41% |
|
| AJRCCM 2008 | ||
|
Triple-kinase |
432 |
- placebo: n = 19/22% |
| Richeldi et al., |
|
- 50 mg × 1: n = 25/29% |
| NEJM 2011 |
|
- 50 mg × 2: n = 27/31% |
| |
|
- 100 mg × 2: n = 20/23% |
| - 150 mg × 2: n = 29/34% |